Simplex Trading
KROS icon

Simplex Trading’s Keros Therapeutics KROS Stock Holding History

Simplex Trading’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$648K Buy
58,700
+49,800
+560% +$769K ﹤0.01% 2966
2025
Q4 		$181K Sell
8,900
-52,600
-86% -$923K ﹤0.01% 4328
2025
Q3 		$972K Sell
61,500
-83,500
-58% -$1.23M ﹤0.01% 3076
2025
Q2 		$1.94M Buy
145,000
+11,900
+9% +$161K ﹤0.01% 2145
2025
Q1 		$1.36M Buy
133,100
+123,000
+1,218% +$1.43M ﹤0.01% 2410
2024
Q4 		$159K Buy
10,100
+10,000
+10,000% +$520K ﹤0.01% 4733
2024
Q3 		$5K Hold
100
– – ﹤0.01% 7621
2024
Q2 		$4K Buy
+100
New +$5.37K ﹤0.01% 8000
2024
Q1 		– Sell
-100
Closed -$3K – 9368
2023
Q4 		$3K Buy
+100
New +$3.14K ﹤0.01% 8103
2023
Q1 		– Sell
-100
Closed -$4K – 9606
2022
Q4 		$4K Hold
100
– – ﹤0.01% 8217
2022
Q3 		$3K Buy
+100
New +$3.47K ﹤0.01% 9106
2022
Q2 		– Sell
-100
Closed -$5K – 10543
2022
Q1 		$5K Hold
100
– – ﹤0.01% 9418
2021
Q4 		$5K Buy
+100
New +$4.99K ﹤0.01% 9530

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Simplex Trading's KROS Position: Q1 2026 in Review

Simplex Trading opened a new position in Keros Therapeutics (KROS) in Q1 2026: 22,288 shares worth $246K. The stake represents ﹤0.01% of the portfolio and ranks #4053 among its holdings. This is a return to the name: Simplex Trading previously reported a position in KROS as recently as Q2 2025.

Simplex Trading first reported a position in KROS in Q2 2022 and has held it in 8 quarters since. The position peaked at $1.21M in Q2 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Simplex Trading held 22,288 shares of Keros Therapeutics worth $246K as of Q1 2026.
  • Keros Therapeutics was a new Simplex Trading position in Q1 2026.
  • Keros Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #4053 holding.
  • Simplex Trading first reported a position in Keros Therapeutics in Q2 2022 and has held it in 8 quarters since.
  • Simplex Trading's Keros Therapeutics position peaked at $1.21M in Q2 2025.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.